Cart
sales@molnova.com
Estradiol valerate
CAS No. 979-32-8
Estradiol valerate( Estradiol 17β-valerate | NSC 17590 )
Catalog No. M16887 CAS No. 979-32-8
β-estradiol 17-valerate (EV) is a synthetic estrogen widely used in combination with other steroid hormones in hormone replacement therapy drugs.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 28 | In Stock |
|
| 5MG | 28 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameEstradiol valerate
-
NoteResearch use only, not for human use.
-
Brief Descriptionβ-estradiol 17-valerate (EV) is a synthetic estrogen widely used in combination with other steroid hormones in hormone replacement therapy drugs.
-
Descriptionβ-estradiol 17-valerate (EV) is a synthetic estrogen widely used in combination with other steroid hormones in hormone replacement therapy drugs.
-
In Vitro——
-
In Vivo——
-
SynonymsEstradiol 17β-valerate | NSC 17590
-
PathwayEndocrinology/Hormones
-
TargetAndrogen Receptor (AR)
-
RecptorAndrogen Receptor
-
Research AreaEndocrinology
-
Indication——
Chemical Information
-
CAS Number979-32-8
-
Formula Weight356.51
-
Molecular FormulaC23H32O3
-
Purity>98% (HPLC)
-
SolubilityDMSO: 71 mg/mL (199.15 mM)
-
SMILESCCCCC(O[C@H]1CC[C@@]2([H])[C@]3([H])CCC4=C(C=CC(O)=C4)[C@@]3([H])CC[C@]12C)=O
-
Chemical Name(17β)-3-hydroxyestra-1,3,5(10)-trien-17-yl valerate
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
BMS-641988
BMS-641988 is a potent, selective, nonsteroidal androgen receptor antagonist with Ki of 1.7 nM, MDA-MB-453 cell IC50 of 16 nM.
-
LGD-3303
LGD-3303 is an orally available, brain-penetrant nonsteroidal selective androgen receptor modulator (SARM) that that shows little or no cross-reactivity with related nuclear receptors.
-
UT-34
UT-34 is a selective and orally active antagonist of second-generation pan-androgen receptor (AR) and degrader(IC50s of 211.7 nM, 262.4 nM and 215.7 nM for wild-type, F876L and W741L AR, respectively), and has anti-prostate cancer efficacy. In LNCaP cells, UT-34 (3-10 μM; 24 hours) treatment inhibits the expression of PSA and FKBP5 and growth of LNCaP cells starting from 100 nM with maximum effect observed at 10 μM.
